About
Type 1 diabetes is a chronic autoimmune disease characterized by insulin deficiency and resultant hyperglycemia. Over 90% of people with newly diagnosed type 1 diabetes have measurable antibodies against specific β-cell proteins, including insulin, glutamate decarboxylase, islet antigen 2, zinc transporter 8, and tetraspanin-7. Most people with a single autoantibody do not progress to type 1 diabetes, but seroconversion to the presence of two or more serum autoantibodies in children is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years. Type 1 diabetes is a heritable polygenic disease with identical twin concordance of 30–70%, sibling risk of 6–7%, and a risk of 1–9% for children who have a parent with diabetes.
Diagnosis
Detecting anti-insulin antibodies early on, aids in clearly defining the autoimmune nature of type I diabetes.
Sebia’s Expertise
Sebia offers a reliable solution for the detection of anti-Insulin antibodies with Alegria Monotest random access solution, and ELISA testing for a high throughput approach. Sebia´s superior antigen coating procedure and the economical all-in-one Alegria system, bring a unique flexibility for optimal workflow efficiency. The all-in-one Alegria Monotest is particularly suited for small series and offers unique flexibility for maximum workflow efficiency with the Alegria 2 system.
Featured resources on Diabetes Type 1
See all resourcesAlegria 2 properties and workflow
Obtain your patients results with high flexibility reliability and efficiency with Alegria 2.
Customer Testimonial about the Alegria 2
The Alegria 2 provides the possibility of giving results to clinicians within a timeframe fitting clinical needs and helps to optimize the patient’s care pathway.
Upcoming events
See all events
Learn more about our unique technologies
- DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018 Jun 16;391(10138):2449-2462. doi: 10.1016/S0140-6736(18)31320-5. PMID: 29916386; PMCID: PMC6661119.
- McLaughlin KA, Richardson CC, Ravishankar A, Brigatti C, Liberati D, Lampasona V, Piemonti L, Morgan D, Feltbower RG, Christie MR. Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes. Diabetes. 2016 Jun;65(6):1690-8. doi: 10.2337/db15-1058. Epub 2016 Mar 7. PMID: 26953162.
- Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013 Jun 19;309(23):2473-9. doi: 10.1001/jama.2013.6285. PMID: 23780460; PMCID: PMC4878912.
- Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014 Jan 4;383(9911):69-82. doi: 10.1016/S0140-6736(13)60591-7. Epub 2013 Jul 26. PMID: 23890997; PMCID: PMC4380133.
- Green, A., Hede, S.M., Patterson, C.C. et al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia 64, 2741–2750 (2021). https://doi.org/10.1007/s00125-021-05571-8
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.